Patents by Inventor Ashique Rafique
Ashique Rafique has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8568721Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: GrantFiled: May 3, 2012Date of Patent: October 29, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20130157313Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: April 18, 2012Publication date: June 20, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8338135Abstract: An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.Type: GrantFiled: December 2, 2011Date of Patent: December 25, 2012Assignee: Regeneron Pharmaceuticals, inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Publication number: 20120258098Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: ApplicationFiled: May 3, 2012Publication date: October 11, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8192741Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: GrantFiled: November 1, 2011Date of Patent: June 5, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20120135010Abstract: An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.Type: ApplicationFiled: December 2, 2011Publication date: May 31, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Patent number: 8183014Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: GrantFiled: September 12, 2011Date of Patent: May 22, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20120045440Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8092802Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.Type: GrantFiled: June 23, 2010Date of Patent: January 10, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Publication number: 20120003697Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: September 12, 2011Publication date: January 5, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean STEVENS, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8080248Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: GrantFiled: May 14, 2010Date of Patent: December 20, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8043617Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: GrantFiled: July 13, 2009Date of Patent: October 25, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20100316636Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: ApplicationFiled: May 14, 2010Publication date: December 16, 2010Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20100316627Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: July 13, 2009Publication date: December 16, 2010Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20100291107Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.Type: ApplicationFiled: June 23, 2010Publication date: November 18, 2010Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Patent number: 7794717Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.Type: GrantFiled: September 4, 2009Date of Patent: September 14, 2010Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Publication number: 20100021476Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.Type: ApplicationFiled: September 4, 2009Publication date: January 28, 2010Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Patent number: 7605237Abstract: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance.Type: GrantFiled: October 2, 2007Date of Patent: October 20, 2009Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
-
Patent number: 7582298Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: GrantFiled: June 1, 2007Date of Patent: September 1, 2009Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20080160035Abstract: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance.Type: ApplicationFiled: October 2, 2007Publication date: July 3, 2008Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Dina M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos